Definition and Goals of Drug Regulatory Affairs and Good Regulatory Practice ZAFES – Curriculum Regulatory Affairs (Module 11) Dr. Christa Schröder Paul-Ehrlich-Institut, Langen Unit „European Procedures“
[email protected]
Content § Information on DRA § Legislation § Marketing Authorisation § Centralised procedure § Mutual recognition procedure § Decentralised procedure
§ Variations § Good Regulatory Practices
Dr. Christa Schröder, Paul-Ehrlich-Institut
2
1
Information on DRA § § § § §
§ § § §
Legislation Guidelines Decisions / statements of key regulators Comments / interpretations Discussions at trade association meetings will be found in journals (Official Journal of the European Community (EU), Bundesanzeiger (DE) , Regulatory Affairs Journal) databases and internet homepages, and is presented at meetings
Dr. Christa Schröder, Paul-Ehrlich-Institut
3
Regulatory Information published by authorities (1) § Official Journal of the European Union The Official Journal is comprised of two series: The L series contains EU legislation including regulations, directives, decisions, recommendations and opinions. The C series contains reports and announcements including the judgments of the European Court of Justice and the Court of First Instance. There is also a supplementary S series containing invitations to tender.
Dr. Christa Schröder, Paul-Ehrlich-Institut
4
2
Regulatory Information published by authorities (2) §
Bundesanzeiger § Der Bundesanzeiger ist neben dem Bundesgesetzblatt ein weiteres Verkündungs- und Bekanntmachungsorgan der deutschen Bundesbehörden. Es wird vom Bundesministerium der Justiz herausgegeben. Zusätzlich ist der Bundesanzeiger Pflichtveröffentlichungsblatt für gerichtliche und sonstige Bekanntmachungen, für alle Handelsregistereintragungen sowie für gesetzlich vorgeschriebene Veröffentlichungen von Jahresabschlüssen und Hinterlegungsbekanntmachungen der Unternehmen. In den letzten Jahren wird die herkömmliche Ausgabe auf Papier mehr und mehr durch den im Internet veröffentlichten elektronischen Bundesanzeiger ersetzt. Dabei erfolgen Veröffentlichungen üblicherweise nicht parallel in beiden Formen.
Dr. Christa Schröder, Paul-Ehrlich-Institut
5
Regulatory Information published by commercial editors § Websites of different associations e.g. § EFPIA - Europ. Fed. Of Pharm. Industries & associations http://www.efpia.org § VFA – Verband Forschender Arzneimittelhersteller http://www.vfa.de § BPI - Bundesverband der Pharmazeutischen Industrie http://www.bpi.de
Dr. Christa Schröder, Paul-Ehrlich-Institut
6
3
Regulatory Information published by commercial editors § Commecial databases e.g.
Dr. Christa Schröder, Paul-Ehrlich-Institut
7
Information on DRA § Links to Key European Institutions § European Commission, Enterprise DG http://ec.europa.eu/enterprise/pharmaceuticals/index en.htm § European Medicines Evaluation Agency EMEA http://emea.europa.eu/ § (National) Medicines Authorities in the European Union http://heads.medagencies.org/
Dr. Christa Schröder, Paul-Ehrlich-Institut
8
4
Information on DRA – Mutual Recognition Product Index of medicinal products approved through the MRP /DCP procedure
Dr. Christa Schröder, Paul-Ehrlich-Institut
9
Website der HMA
Dr. Christa Schröder, Paul-Ehrlich-Institut
10
5
Information on DRA - European Public Assessment Report
Dr. Christa Schröder, Paul-Ehrlich-Institut
11
Information on DRA – National lists of approved products § E.g. Rote Liste (Germany)
Dr. Christa Schröder, Paul-Ehrlich-Institut
12
6
Hierachy of the Community texts
Pharmaceutical Law 1. Binding Legislation Regulations (Verordnung) (e.g. 726/2004/EC) directly binding Directives (Richtlinie) national law (e.g. 2001/83/EC 14. AMG Novelle)
2. Soft law – not legally binding Recommendations (Council, Parl.) Guidelines (EU Commission, EMEA, CHMP, ICH, WHO) Notice to Apllicants
Dr. Christa Schröder, Paul-Ehrlich-Institut
13
Rules Govering Medicinal Products in the EU (Eudralex) § Volume 1 – Community legislation § Volume 2 – The Notice to Applicants (NtA) § Volume 2A – Procedures for Marketing Authorisation § Volume 2B – Presentation and content of the application dossier
§ Volume2C – Regulatory Guidelines § Volume 3 - Guidelines – Quality, safety, efficacy § Volume 4 - guide to Good Manufacturing Practice for Medicinal products § Volume 5-8 – Veterinary issues § Volume 9 – Pharmacovigilance § Volume 10 – Good Clinical Practice
Dr. Christa Schröder, Paul-Ehrlich-Institut
14
7
Basic Classification of Medicines § Medicinal products / Medicinal devices for human or veterinary use § New active substances / Generic medicinal Products § Biological Products / Biotechnology Products § Immunological Medicinal Products § Prescription / non-prescription § Herbal Medicinal Products / Traditional Herbal Medicinal Products § Radiopharmaceuticals
Dr. Christa Schröder, Paul-Ehrlich-Institut
15
Basic Classification of Medicines § Directive 2001/83/EC, Article 1 (2) Medicinal Product § Any substance or combination of substances presented for treating or preventing disease in human beings § Any substance or combination of substances which may be administered to human beings with a view to making medical diagnosis or to restoring, correcting or modifying physiological functions in human beings § Article 2(2) In cases of doubt, where, taking into account all ist characteristics, a product may fall within the definition of a „medicinal product“ and within the definition of a product covered by other Community legislation the provisions of this Directive shall apply
Dr. Christa Schröder, Paul-Ehrlich-Institut
16
8
Basic Classification of Medicines Acc. To Directive 2001/83/EC Biological Product § A biological medicinal product is a product, the active substance of which is a biological substance § Produced by or extracted from a biological source § That needs for its characterization and the determination of ist quality a combination of physiochemical-biological testing, together with the production process and ist control § The following shall be considered as biological medicinal products: § Medicinal products derived from human blood and human plasma as defined, respectively in paragraphs (4) and (10) of Article 1 § Medicinal products falling within the scope of Part A of the Annex to Regulation (EEC) No 2309/93 § Advanced therapy medicinal products as defined in Part IV of this Annex
Dr. Christa Schröder, Paul-Ehrlich-Institut
17
Basic Classification of Medcines Biotechnology Product (Annex to Regulation 726/2004/EC)
Dr. Christa Schröder, Paul-Ehrlich-Institut
18
9
Marketing Authorisation Options § Centralised Procedure
§ Mutual Recognition Procedure
Mutual Recogntion Centralised Decentralised
National
§ Decentralised Procedure
§ National Procedure
Dr. Christa Schröder, Paul-Ehrlich-Institut
19
CENTRALISED PROCEDURE FOR MARKETING AUTHORISATION APPLICATIONS EVALUATION
10
Optional Scope - Regulation (EC) No 726/2004
§ Article 3(1): “mandatory” scope § Article 3(2): “optional” scope § (a) new active substance not authorised; or § (b) significant therapeutic, scientific or technical innovation or interests of patients at Community level.
Dr. Christa Schröder, Paul-Ehrlich-Institut
21
Compulsory scope of Centralised procedure/ Therapeutic areas Regulation 2004/726/EC: Medicinal products to be authorised by the Community include medicinal products for human use containing a new active substance which, on the date of entry into force of this Regulation, was not authorised in the Community, for which the therapeutic indication is the treatment of any of the following diseases: -acquired immune deficiency syndrome -cancer -neurodegenerative disorder -diabetes and with effect from 20 May 2008: -auto-immune diseases and other immune dysfunctions -viral diseases
Dr. Christa Schröder, Paul-Ehrlich-Institut
22
11
Overview of the Centralised Procedure Day 0 - 120 Presubmission
Primary evaluation
CLOCK STOP
Day 121 - 210 Secondary Decision evaluation
Opinion/
LAUNCH
Post authorisation Activities Dr. Christa Schröder, Paul-Ehrlich-Institut
Quelle: EMEA
23
Landscape
CHMP Committee for Medicinal Products for Human Use
Other groups
COMP Committee for Orphan Medicinal Products
13 WPs 7 Scientific Advisory Groups
Working Parties Quelle: EMEA
Dr. Christa Schröder, Paul-Ehrlich-Institut
24
12
CHMP Working Parties Scientific Advisory Groups (SAGs (SAGs))
Scientific Advice WP
Paediatric WP
- HIV/Viral Diseases - AntiAnti- Infectives (not HIV) - Cardiovascular - Central Nervous System - Diabetes & Endocrinology - Diagnostics - Oncology
Safety WP Efficacy WP
CHMP
Quality WP
Pharmacogenetics WP
Pharmacovigilance WP
Gene Therapy WPWP- Cell based therapy WP Vaccine WP
Biological WP Blood Products WP
(Pre(Pre-)clinical WP on comparability + specific adad-hoc working groups or subgroup meetings when needed
Quality Review of Documents
Dr. Christa Schröder, Paul-Ehrlich-Institut
Quelle: EMEA
25
Dossier Assessment Dossier Assessment Based on Assessment by Rapp/Co-Rapp Peer Review Precise and operational format Reports to CHMP Scientific Advice
SAWP Possible oral explanations + BWP VWP SWP QWP
Quelle: EMEA
MAA •Initial MAA •List of Questions •Prior to Opinion •Possible Oral explanation •Variations •Line Extensions •Referrals
PMF VAMF
BWP
Pandemic flu MAA (future)
VWP
BWP VEG SAG •Anti-infectives (not HIV) •Diagnostics •central Nervous System •Cardiovascular •Diabetes / Endocrinology SWP QWP
Dr. Christa Schröder, Paul-Ehrlich-Institut
MA Post Authorisation Pharmacovigalance
PhVWP BWP VWP SWP
26
13
Where to find Information about EMEA
Dr. Christa Schröder, Paul-Ehrlich-Institut
27
Where to find WP and SAGs information
Dr. Christa Schröder, Paul-Ehrlich-Institut
28
14
PrePre-Submission phase
PrePre-submission
-1 m Request for accelerated procedure -7/-6 m Appointment Rapporteurs + Pre- submission meetings - 18m/-12m Filing strategy/ Confirmation Eligibility Invented name review Quelle: EMEA
Orphan Drug designation
- 12 to -36m Scientific Advice Dr. Christa Schröder, Paul-Ehrlich-Institut
29
Submission / Validation Phase 10 working days
Submission Application Modules 1-5
Acceptability of application
D1 Start of procedure
PTL (with relevant PTMs): check Administrative part Technical part (compliance with legal/regulatory requirements) Possible interaction with (Co-) rapporteurs to discuss questions on admissibility
No scientific evaluation at this stage Quelle: EMEA
Dr. Christa Schröder, Paul-Ehrlich-Institut
30
15
M od ul e1
Common Technical Document (CTD) Not part of CTD e.g Environmental risk assessment Orphan Exclusivity, Risk Management System
1
Nonclinical Overview
Mo d
u
le Ov Q er ua 2 all lit Su y mm ar y
Regional Administrative Information
3
Quality Data Study Reports
Clinica l Overview
2 Nonclinical Summaries
4
Nonclinical Data Study Reports
Clinical Summary
5
Clinical Data Study Reports
Raw Data
Quelle: EMEA
CT D
Dr. Christa Schröder, Paul-Ehrlich-Institut
31
Primary Evaluation Phase
Stop Clock
D 1 D 80
D 100
Rapp./Corapp AR
CHMP EMEA
Quelle: EMEA
CHMP comments + peer reviewer
Applicant
D 112
D 120
Peer review CHMP consolidated List of Questions TeleApprovability/nonconference approvability
Applicant
Dr. Christa Schröder, Paul-Ehrlich-Institut
32
16
Secondary Evaluation Phase
Opinion
D 121
D 150
D 180
Day 181
Joint Rapp./ Co-rapp. AR
Hearing?
Hearing
Benefi t
Risk
D 210
Opinion
D 170
Comments CHMP CHMP EMEA
Consensus? Vote?
Applicant Dr. Christa Schröder, Paul-Ehrlich-Institut
Quelle: EMEA
33
Different type of MA Conditional MA
MA under Exceptional Circumstances § Comprehensive data cannot be provided (specific situations foreseen in the legislation)
§ § § §
positive benefit-risk balance comprehensive data likely to be provided unmet medical fulfilled benefit to public health of immediate availability outweighs risk inherent – additional data is required
§
Authorisation valid for one year, on a renewable basis
§
Once the pending studies are provided, it can become a “normal” marketing authorisation
§ Reviewed annually to reassess the risk-benefit balance § Will not (normally) lead to completion of the dossier and become a “normal” market authorisation
Dr. Christa Schröder, Paul-Ehrlich-Institut
34
17
Accelerated procedure Ø Scientific opinion in 150 days (instead of 210) § 1st phase similar § Day 120 Opinion or List of outstanding issues § Day 121-150 Oral explanation if applicable + Opinion
35
Dr. Christa Schröder, Paul-Ehrlich-Institut
Overview Orphan Medicinal Products
Orphan Designation mandatory access to CP
Orphan Designation By COMP/EC Orphan Designation Procedure
Protocol assistance by SAWP
CP
Protocol assistance procedure
EC Decision
Medicinal Products for the Community CHMP Opinion
Scientific Advice by SAWP
Scientific Advice Procedure
CHMP Opinion
CP: Standard Evaluation or Accelerated Procedure
MA
Conditional Approval Exceptional Circumstances “Normal” Circumstances EC Decision
MA Compassionate Use Procedure
Compassionate Use Procedure
Compassionate Use Procedure
Compassionate Use Procedure
Medicinal Products for outside the community in collaboration with WHO WHO eligibilit y
Scientific Advice Procedure WHO eligibility
Scientific Advice by SAWP CP Dr. Christa Schröder, Paul-Ehrlich-Institut
CHMP Opinion
36
18
Compassionate Use (Reg 726/2004/EC Art. 14 and Dir 2001/83/EC) § Supply of an unlicensed medicinal product to patients for whom no standard alternative therapies are available § Usually reserved for the treatment of serious diseases § Takes place before or during the assessment procedure for the granting of a MA and ends with the result of the procedure § Enables innovative drugs to be made available to patients during the development programme
37
Dr. Christa Schröder, Paul-Ehrlich-Institut
Getting a MA for a new medicinal product CHMP Opinion(s) English
Translation to all other 19 official European languages + Bulgarian & Romanian
(as signed off by the CHMP Chairman)
day 0 Quelle: EMEA
Version
Transmission
Commission
M.S.
Dr. Christa Schröder, Paul-Ehrlich-Institut
Applicant(s) day 27 38
19
EPAR - European Public Assessment Report = CHMP Assessment Report after deletion of information of
commercially confidential nature Summary authorised presentations
available in all EU languages available in English
Package Leaflet
All readers Patients
Summary of Product Characteristics
Health professionals
Labelling
Pharmacists/patients
Authorisation Scientific Basis
Scientific community Health professionals
Steps taken for the assessment of the product
Quelle: EMEA
All readers
Anyone interested
Steps taken after granting Anyone interested the Marketing Authorisation 39 Dr. Christa Schröder, Paul-Ehrlich-Institut
European Public Assessment Report
Dr. Christa Schröder, Paul-Ehrlich-Institut
40
20
Mutual Recognition Procedure Decentralised procedure
Scope of MRP/DCP: National Marketing Authorisation - (1)
§ new active substances (if not mandatory for the centralised procedure) § generic medicinal products to national (and centralised) authorised reference medicinal products (if not a biotechnological medicinal product) § informed consent § bibliographic applications (well established use (WEU))
Dr. Christa Schröder, Paul-Ehrlich-Institut
42
21
Scope of MRP/DCP: National Marketing Authorisation - (2)
cont.
§ § § §
line extensions to national authorisations known substances in new combination homeopathics traditional herbal medicinal products
Dr. Christa Schröder, Paul-Ehrlich-Institut
43
MRP and DCP
Two routes to receive a MA 1. Mutual recognition procedure (MRP) where the medicinal product has already received in a MS a MA at the time of application or
2. Decentralised procedure (DCP) where the medicinal product has not received in a MS a MA at the time of application
Dr. Christa Schröder, Paul-Ehrlich-Institut
44
22
MRP and DCP
Procedures
Dr. Christa Schröder, Paul-Ehrlich-Institut
45
Co-Ordination Group for Mutual Recognition and Decentralised Procedures (CMD)
Dr. Christa Schröder, Paul-Ehrlich-Institut
46
23
MRP
DCP
MA RMS
Dossier
Dossier
RMS CMSs 120 days
AR, SPC, PL, label
90 days
Update of AR
MA RMS
Applicant
Dossier
RMS
CMSs
Draft AR, SPC, PL
Proposal for changes (CMSs)
90 days
Final SPC, PL, label
MA CMS
MA CMS
Discussion between all MSs
Final AR, SPC, PL
MA CMS
MA CMS
Dr. Christa Schröder, Paul-Ehrlich-Institut
MA CMS
MA CMS
MA RMS 47
Marketing Authorisation EU DCP
MRP §
§ § §
§ §
First application to the Reference Member State and granting of a national Marketing Authorisation (MA) – Assessment Report (AR) For products with an existing national MA the RMS has to update the AR Identical applications to selected Concerned Memeber States (CMS) If agreement is reached after 90 days – subsequent national Authorisations in the cMS (Authorisation dates different) If no agreement is reached – further 60 days negotiation phase in the Coordination Group (CMD) 1 SPC, Package leaflet, labelling; different brand names possible
§ § § § §
§ §
Only possible, if a national MA has not yet been granted Identical applications to be submitted simultanously to RMS and CMS RMS prepares preliminary draft AR – comments by the cMS RMS distributes Draft AR If agreement is reached after 90 days – subsequent national Authorisations in the RMS and CMS (Authorisation dates different) If no agreement is reached – further 60 days negotiation phase in the Coordination Group (CMD) 1 SPC, Package leaflet, labelling; different brand names possible
Dr. Christa Schröder, Paul-Ehrlich-Institut
48
24
Variations § Definition of a Variation Any amendment to the documentation – which is the legal basis for the Marketing Authorisátion of the medicinal product – archived at the competent authority
Dr. Christa Schröder, Paul-Ehrlich-Institut
49
Classification of Variations Acc to Reg‘s 1085/2003/EC and 1084/2003/EC Annexes § Urgent safety restrictions: immediate information of the EMEA / competent authorities § Type IA and IB (minor variations): Notification – Decision by RMS § Type II is an approval procedure e.g. additional therapeutic indication § Extension Application – leads to a Marketing Authorisation
Dr. Christa Schröder, Paul-Ehrlich-Institut
50
25
Good Regulatory Practices Good Regulatory Practices (GRP) can be defined as: M. Korteweg, EMEA: A quality system to ensure that the users of medicinal products, the applicants, the regulators are satisfied with the scientific advice, opinions, the establishment of Maximum Residue Levels, inspection and assessment reports and related documents, taking into consideration legal requirements and guidance in order to protect and promote human and animal health.
Dr. Christa Schröder, Paul-Ehrlich-Institut
51
Good Regulatory Practices in a growing network of authorities § 1988 ICH Conference in Japan: harmonisation of technical requirements for registration of pharmaceuticals in human use § Authorities worked more and more together (CTD, exchange of information, etc) – EU enlargement § Implies a common understanding of technical /regulatory requirements and consistency in interpretation and application whether in the area of assessments, inspections or pharmacovigilance § Need to ensure quality, consistency in a growing EU – establishment of management systems
Dr. Christa Schröder, Paul-Ehrlich-Institut
52
26
Tools § Paul-Ehrlich-Institut: Peer Review § Medicines Agencies‘ Network: Benchmarking
Dr. Christa Schröder, Paul-Ehrlich-Institut
53
The Peer Review Group as a tool to drive Good Regulatory Practice § PEI Peer Review Group: Definition The PRG is a PEI-internal scientific panel, which by discussion of assessment reports… …widens the scientific basis of decisions made by internal and external assessors, …provides assistance in critical / controversial issues. ...provides access to „regulatory memory“
Quelle: C. Schneider
Dr. Christa Schröder, Paul-Ehrlich-Institut
54
27
Regulatory Peer Review – why? § Regulatory decisions should include the following principles: § Based on science § At least for biological and biotechnological medicinal products: Bridging quality – non-clinical – clinical part § Consistency with previous regulatory decisions § …for similar active substances from the same class § …for active substances based on a similar mechanism of action § …for similar clinical indications
§ Requirements for Applicants should be similar
Quelle: C. Schneider
Dr. Christa Schröder, Paul-Ehrlich-Institut
55
The Peer Review Group as a tool to drive Good Regulatory Practice PRG meeting mandatory if: PEI is Scientific Advice/Protocol AssistanceCo-ordinator PEI is (Co-) Rapporteur in centralised procedure Scope recently extended: PEI is Reference Member state in a MRP/DC Referrals if induced by PEI National Procedures (except certain cases, e.g. not virus-inactivated blood components for transfusion, parallel imports, )
Quelle: C. Schneider
Dr. Christa Schröder, Paul-Ehrlich-Institut
56
28
EU Medicines Network What is BENCHMARKING Of EUROPEAN MEDICINES AGENCIES BEMA? Compare To enrich, to learn, to find best practices, which are (cost)-effective, efficient, feasible
Dr. Christa Schröder, Paul-Ehrlich-Institut
57
BEMA - Aim § Identify and share best practices across the network of EU and EEA medicines agencies § Comparing individual management systems or processes with the aim of learning from one another § Carried out by colleagues from another competent authority who are fulfilling the same responsibilities under legislation in different and complementary ways learning from one another § The purpose of BEMA is to enable mutual exchange of information, with a view to introducing improvement measures within agencies
Dr. Christa Schröder, Paul-Ehrlich-Institut
58
29
Thank you very much!
Dr. Christa Schröder, Paul-Ehrlich-Institut
59
30